However, strong evidence supporting the use of sacubitril/valsartan to reduce the absolute risk of hyperkalemia and worsening renal function in HF patients with renal dysfunction is still lacking, although it can cause a slower rate of decline in renal function compared to renin–angiotensin system inhibition alone. The gene discussed is REN; the disease is hydrops fetalis.